Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of Shingrix Efficacy and Safety (ZOSTER-101)
NCT05371080Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Aug 2022
- Primary completion
- Aug 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 18
01
Overview
Phase 3, open-label trial of herpes zoster vaccine (recombinant, adjuvanted) in herpes zoster (HZ) (4 arms), sponsored by GSK. Primary endpoint: Number of participants with confirmed Herpes Zoster cases. Started Aug 2022; status: active, not recruiting.
02
Drugs
herpes zoster vaccine (recombinant, adjuvanted)
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT05371080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05371080.